文献速递浆细胞疾病

染色体1q21异常识别具有预后和临床意义的超高危骨髓瘤

Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
PubMed 文献 · Am J Hematol · 2022-06-29

该研究分析912例连续新诊断症状性多发性骨髓瘤患者,用FISH检测+1q21及其拷贝数变化。27.3%患者有+1q21,其中3拷贝占16.4%、4拷贝及以上占10.9%。+1q21与更晚期ISS分期、并发其他细胞遗传学异常及晚期R-ISS分期相关,无进展生存和总生存均更差,且拷贝数无额外预后影响。+1q21在多因素分析中为独立预后因素,在R-ISS-3患者中预后更差,识别出超高危亚组,并在272例独立队列中验证。

要点

  • 新诊断多发性骨髓瘤中+1q21发生率为27.3%,其中3拷贝占16.4%、4拷贝及以上占10.9%。
  • +1q21患者无进展生存和总生存更差,但1q21拷贝数无额外预后影响。
  • R-ISS-3合并+1q21患者总生存仅16个月,构成超高危亚组,并在独立队列验证。

核心结论

  • +1q21与更晚期疾病、更差的无进展生存和总生存相关,R-ISS-3合并+1q21患者预后极差,构成超高危组。

研究设计与样本

  • 分析912例连续症状性多发性骨髓瘤患者,用FISH评估+1q21及其拷贝数变化,并在272例独立队列中验证。

主要发现

  • 初诊时249例(27.3%)有+1q21,其中150例(16.4%)为3拷贝、99例(10.9%)为4拷贝及以上。
  • +1q21与晚期ISS分期相关(p = .003),与并发其他细胞遗传学异常及晚期R-ISS分期相关(p < .001)。
  • +1q21患者无进展生存更差(中位34 vs. 20个月,p < .001),总生存更差(中位75 vs. 44个月,p < .001)。
  • 1q21拷贝数无额外预后影响。
  • 校正R-ISS、年龄、治疗和HDM后,+1q21仍为无进展生存(p < .001)和总生存(p = .008)的独立预后因素。

关键数值与推荐

  • +1q21在R-ISS-3患者中预后更差,总生存仅16个月,而无+1q21的R-ISS-3患者为46个月(p < .001)。
  • 在272例独立队列中验证了上述发现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Numerical abnormalities of chromosome 1q (+1q21) are common in patients with newly diagnosed multiple myeloma (MM) but their prognostic impact remains a matter of debate. In addition, the impact of the number of copies of 1q21 is not known. We analyzed 912 consecutive patients with symptomatic MM to evaluate the prognostic implications of +1q21 and of their copy number variations, as assessed by FISH. At the time of initial diagnosis, 249 (27.3%) patients had +1q21, of which 150 (16.4%) had 3 copies and 99 (10.9%) had 4 or more copies. Presence of +1q21 was associated with advanced ISS stage (p = .003), concurrent presence of other cytogenetics aberrations and advanced R-ISS stage (p < .001). Patients with +1q21 had inferior PFS (median 34 vs. 20 months, p < .001) and OS (median 75 vs. 44 months, p < .001) but the copy number of 1q21 had no additional prognostic impact. In multivariate analysis, adjusting for R-ISS, age, treatment and HDM, +1q21 remained an independent prognostic factor both for PFS (p < .001) and OS (p = .008). The detrimental prognostic effect of +1q21 was more profound in R-ISS-3 patients, identifying a subgroup with OS of just 16 months (vs. 46 for R-ISS-3 without +1q21, p < .001). We further validated our findings in an independent cohort of 272 patients. In conclusion, the presence of +1q21 is associated with more advanced disease, inferior PFS, and OS but especially patients with R-ISS-3 disease and +1q21 have a very poor outcome comprising an ultra-high-risk group.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kastritis E, Migkou M, Dalampira D, et al. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol. 2022. PMID: 35731917. doi:10.1002/ajh.26639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。